Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for allegedly misleading investors regarding its financial projections and business model following its spin-off from Labcorp [3][4]. Company Overview - Fortrea is a global clinical research organization (CRO) that assists in the development of pharmaceutical and medical device products. It was spun off from Labcorp in June 2023 and had ongoing long-term projects at that time [3]. Allegations and Financial Misrepresentation - The lawsuit claims that Fortrea overestimated the revenue from its Pre-Spin Projects for 2025, overstated cost savings from phasing out transition service agreements (TSAs), and inflated its EBITDA targets for 2025, leading to a misleadingly positive outlook on its post-spin-off business model [5]. - Specific allegations include: 1. Overestimation of revenue from Pre-Spin Projects for 2025 [5]. 2. Overstatement of cost savings from the elimination of TSAs [5]. 3. Inflated EBITDA targets for 2025 [5]. Market Reactions and Stock Performance - Following a downgrade by Jefferies on September 25, 2024, which cited weaknesses in Fortrea's CRO model and the misleading nature of its cost savings, the stock dropped over 12% [5]. - A subsequent downgrade by Baird Equity Research on December 6, 2024, after the cancellation of two conferences, led to an additional 8% decline in stock price due to concerns over Fortrea's inconsistent performance and communication [5]. - On March 3, 2025, Fortrea reported disappointing Q4 and full-year 2024 results, admitting that its revenue and EBITDA goals for 2025 were unrealistic, resulting in a stock drop of more than 25% [5].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 3, 2023, and February 28, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Fortrea Holdings Inc. overestimated revenue contributions from its long-term projects, known as the Pre-Spin Projects, for the year 2025 [2]. - It is alleged that the company overstated potential cost savings from exiting transition services agreements, leading to inflated EBITDA targets for 2025 [2]. - The viability of Fortrea's post-spin-off business model and its financial prospects were reportedly overstated, resulting in materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 1, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the “Class Period”), of the important August 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Fortrea securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Fortrea Holdings, Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Fortrea’s business, operations, and prospects, including allegations that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company’s 2025 ea ...

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fortrea Holdings, Inc. (NASDAQ: FTRE) between July 3, 2023 and February 28, 2025, both dates inclusive (the “Class Period”), of the important August 1, 2025 lead plaintiff deadline. SO WHAT: If you purchased Fortrea securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Fortrea Holdings (FTRE) To Contact Them To Discuss Their Options If you purchased or acquired securities in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) --  Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law ...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=157779&from=3 CLASS PERIOD: Ju ...

NEW YORK, July 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE).Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=157761&from=4CLASS PERIOD: July 3, 20 ...

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for allegedly misleading investors regarding its financial projections and business model following its spin-off from Labcorp [1][3][4]. Company Overview - Fortrea is a global clinical research organization (CRO) that assists in the development of pharmaceutical and medical device products. It was spun off from Labcorp in June 2023 and had ongoing long-term projects at that time [3]. Allegations of Misleading Information - The lawsuit claims that Fortrea overestimated the revenue from its Pre-Spin Projects for 2025, overstated cost savings from phasing out transition service agreements (TSAs), and inflated its EBITDA targets for 2025, presenting an overly optimistic view of its post-spin-off business model [5]. Market Reactions and Stock Performance - On September 25, 2024, Jefferies downgraded Fortrea from Buy to Hold, citing weaknesses in the CRO model and a lack of real cost savings, leading to a stock drop of over 12% [5]. - On December 6, 2024, Baird Equity Research downgraded Fortrea to Neutral after the company canceled two conferences, resulting in an additional 8% decline in stock price [5]. - On March 3, 2025, Fortrea reported disappointing Q4 and full-year 2024 results, admitting that its revenue and EBITDA goals for 2025 were unrealistic, causing the stock to drop more than 25% [5].